Esquemas terapêuticos encurtados para o tratamento de malária por Plasmodium vivax

Silva, Rita do Socorro Uchôa da; Pinto, Ana Yecê Das Neves; Calvosa, Vanja Suely Pachiano; Souza, José Maria de.
Rev. Soc. Bras. Med. Trop ; 36(2): 235-239, mar.-abr. 2003. tab
Artigo em Português | LILACS | ID: lil-340902

Documentos relacionados

  1. Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
  2. Higher-Dose Primaquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria.
  3. Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
  4. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
  5. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
  6. Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
  7. Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.
  8. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
  9. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
  10. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.